One to watch: Phytopharm
Phytopharm's origins were focussed on attempts to develop products extracted from botanical sources based on Chinese remedies. This has now developed into the synthetic manufacturing of Cogane and Myogane, the former a potential treatment for Parkinson's and motor neuron, the latter a treatment for glaucoma.
By its own admission, Phytopharm is a high-risk prospect. However, the trials for both Cogane and Myogane have proved encouraging. The group has received a grant of $1.16 million (7520,000) from the Michael J Fox Foundation and, following an equity issue in 2009, has sufficient cash to fund a development programme until the trials are concluded.
Advertisement
Hide AdAdvertisement
Hide AdFor those looking for a classic high-risk "high-reward" investment in a developing pharmaceutical company, Phytopharm could be interesting.
Phytopharm
7.8p +0.05p
Scotsman says BUY
• The value of your investment could fall and you may get back less than you invested. You should take professional advice if you have any doubt on the suitability of this stock for your portfolio.
BROKER SNAPS
JD Wetherspoon
423.4p -5.5p
Broker says REDUCE
NUMIS cut its rating on pubs operator JD Wetherspoon from "hold" to "reduce" over concerns about its "squeezed bottom". The broker said: "Our concern is JD Wetherspoon's efforts to pass on higher costs to protect margins could disproportionately reduce like-for-like volumes and profits."
Kingfisher
251p -6.3p
Broker says BUY
FRENCH government data released on Friday showed a slowdown in the sales growth of DIY products, according to Espirito Santo. The broker said it would be keeping a close eye on the next set of quarterly figures and any affect they may have on Kingfisher, which owns the B&Q chain in the UK, along with stores in France.